
Genentech’s Enspryng (Satralizumab) Cuts Relapse Risk by 68%, Showing Promise as First Treatment for MOGAD
Genentech’s Enspryng (Satralizumab) Cuts Relapse Risk by 68%, Showing Promise as a Potential First Treatment for MOGAD Genentech, a member of the Roche Group, has announced compelling new results from…












